Xenon Pharma Will Offer Business, Milestone Update at Needham Conference

Xenon Pharmaceuticals Inc. XENE, a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a business update, including progress toward milestones, at the Needham Healthcare Conference at 12:50 pm ET on Tuesday, April 12, 2016, in New York City. Anticipated Milestones Xenon's partner Teva Pharmaceutical Industries Ltd. is currently conducting a randomized, double-blind, placebo-controlled Phase 2b clinical trial for TV-45070 in patients with post-herpetic neuralgia. Previously, the Company had anticipated results in the second half of 2016; however, Teva updated its forecast and now expects results in the first half of 2017. Xenon's partner Genentech, a member of the Roche Group, is currently conducting two Phase 1 clinical trials for GDC-0276 and GDC-0310, which are both oral, selective Nav1.7 small-molecule inhibitors being developed for the potential treatment of pain. Both Phase 1 clinical trials are ongoing, and pending a full assessment of the results, Genentech intends to initiate a Phase 2 clinical trial in 2016. The research term for Xenon's second collaboration with Genentech, which is centered on pain genetics, has been extended for another year until March 2017. XEN801 is a topical stearoyl Co-A desaturase-1, or SCD1 inhibitor, being developed for the treatment of moderate to severe acne. Data from the Phase 1 clinical trial completed in December 2015 supported progressing to a Phase 2 clinical trial, which was initiated in February 2016. Xenon expects to enroll approximately 150 patients with moderate to severe acne, with topline results expected in the fourth quarter of 2016. Xenon's development of a Nav1.6 sodium channel inhibitor for the treatment of rare childhood epilepsy disorders – such as Dravet Syndrome, an orphan disease of severe childhood epilepsy – continues to progress, and results from early in vivo studies have been encouraging. Xenon expects to identify a development candidate in 2016 and file an investigational new drug (IND) application in the first half of 2017. Xenon will continue to leverage its drug discovery platform to identify validated drug targets and develop new product candidates, and expects to provide updates as new drug discovery programs advance in 2016. Xenon is eligible to receive a royalty on commercial sales of Glybera®, which is licensed to uniQure Biopharma B.V. for the treatment of the orphan disorder lipoprotein lipase deficiency. The first patient treated with Glybera as a commercially-available gene therapy was announced by uniQure in November 2015 and enabled by its commercialization partner in the EU, Chiesi Farmaceutici S.p.A. An audio webcast of the presentation will be broadcast live on the investors section of Xenon's website at www.xenon-pharma.com and will be available for replay for 30 days following the presentation.